SunLink Health Systems, Inc. Announces Fiscal 2021 Second Quarter Results, Recognition of a Portion of Provider Relief Funds Received, and COVID-19 Update
SunLink Health Systems (SSY) reported earnings from continuing operations of $3,146,000 ($0.46 per share) for Q2 fiscal 2021, up from $203,000 ($0.03 per share) last year.
Net earnings surged to $3,074,000 from a net loss of $42,000. However, consolidated net revenues fell 20.7% to $10,150,000, mainly due to decreased revenues in healthcare and pharmacy segments amid the COVID-19 pandemic. Operating losses were reported at $254,000 compared to profits in the same quarter last year. The company also received $5,008,000 from the Provider Relief Funds under the CARES Act.
- Earnings from continuing operations increased to $3,146,000 ($0.46 per share) from $203,000 ($0.03 per share) YOY.
- Net earnings improved to $3,074,000 from a loss of $42,000 in Q2 2019.
- Total Provider Relief Funds received amounted to $5,008,000.
- Consolidated net revenues decreased by 20.7% to $10,150,000 compared to $12,805,000 in Q2 2019.
- Operating loss for the quarter was $254,000, down from an operating profit of $281,000 in Q2 2019.
- Continued uncertainty regarding the impact of COVID-19 on future revenues and expenses.
SunLink Health Systems, Inc. (NYSE American: SSY) today announced earnings from continuing operations of
Our Healthcare and Pharmacy segments received approximately
Consolidated net revenues from continuing operations for the quarters ended December 31, 2020 and 2019 were
SunLink reported an operating loss for the quarter ended December 31, 2020 of
Loss from discontinued operations was
For the six months ended December 31, 2020, SunLink reported earnings from continuing operations of
Consolidated net revenues from continuing operations for the six months ended December 31, 2020 and 2019 were
Loss from discontinued operations was
COVID-19 Pandemic
A novel strain of coronavirus (“COVID-19”) was declared a global pandemic by the World Health Organization on March 11, 2020. As previously reported, we have been monitoring the COVID-19 pandemic and its impact on our operations, and we have taken significant steps intended to minimize the risk to our employees and patients and the pandemic’s effect on our business. Since the beginning of the pandemic, our Healthcare and Pharmacy segments’ business have experienced reduced admissions and/or negative sales trends in certain areas as well as increased costs and operational inefficiencies due to measures taken to protect our employees and patients and by access controls and other restrictions implemented in response to the pandemic. The pandemic has not, however, materially affected our ability to maintain critical business operations, which are being conducted substantially in accordance with our understanding of applicable government health and safety protocols and guidance issued in response. Nevertheless, as in many healthcare environments, we have experienced COVID-19 illness, including deaths, in our Healthcare Segment and some employees have tested positive and been placed on leave or in quarantine. In late December 2020, we began receiving allotments of COVID-19 vaccine and have begun to vaccinate patients, providers, employees, and staff in accordance with the protocols and guidelines in the states where we operate. Not all such individuals have been vaccinated to date and some individuals have not consented to vaccination.
From the fourth quarter of fiscal 2020 through December 31, 2020, our Healthcare and Pharmacy segments received approximately
The PRF distributions are not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding. Such funds under the PRF are accounted for as government grants and are recognized on a systematic and rational basis once there is reasonable assurance that the applicable terms and conditions required to retain the funds have been met. We are reporting
Forgiveness of PPP loans may be available if the loans are used to pay wages, rent, utilities and interest on certain debt during the eight-week period following receipt of the loan proceeds, subject to Federally-established terms and conditions. There can be no assurance, however, that any of the PPP loans received will be forgiven, or if forgiven, the amount of such forgiveness. Loan proceeds not forgiven are payable over two years at a
Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its assets and operations. Our ability to make estimates of the effect of the COVID-19 pandemic on revenues, expenses or changes in accounting judgments that have had or are reasonably likely to have a material effect on our financial statements is currently limited. The nature and extent of the effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic; government actions to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those that affect our hospital, nursing home and pharmacy operations; and existing and potential government assistance that may be provided, including the requirements applicable to PRF receipts and PPP loans.
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the company’s business strategy. These forward-looking statements are subject to certain risks, uncertainties, and other factors, which could cause actual results, performance, and achievements to differ materially from those anticipated. Certain of those risks, uncertainties and other factors are disclosed in more detail in the company’s Annual Report on Form 10-K for the year ended June 30, 2020 and other filings with the Securities and Exchange Commission which can be located at www.sec.gov.
SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES | |||||||||||||||||
FISCAL 2021 SECOND QUARTER RESULTS., RECOGNITION | |||||||||||||||||
OF A PORTION OF PROVIDER RELIEF FUNDS RECEIVED | |||||||||||||||||
AND COVID-19 UPDATE | |||||||||||||||||
Amounts in 000's, except per share and volume amounts | |||||||||||||||||
CONSOLIDATED STATEMENTS OF EARNINGS (LOSS) | |||||||||||||||||
Three Months Ended December 31, 2020 |
|
Six Months Ended December 31, 2020 |
|||||||||||||||
|
2020 |
|
2019 |
|
2020 |
|
2019 |
||||||||||
|
|
|
% of Net |
|
|
|
% of Net |
|
|
|
% of Net |
|
|
|
% of Net |
||
|
Amount |
|
Revenues |
|
Amount |
|
Revenues |
|
Amount |
|
Revenues |
|
Amount |
|
Revenues |
||
Net Revenues |
|
|
|
|
|
|
|
|
|||||||||
Costs and Expenses: | |||||||||||||||||
Cost of goods sold | 3,918 |
|
5,097 |
|
7,988 |
|
9,441 |
|
|||||||||
Salaries, wages and benefits | 4,226 |
|
4,849 |
|
8,611 |
|
9,758 |
|
|||||||||
Supplies | 280 |
|
334 |
|
504 |
|
653 |
|
|||||||||
Purchased services | 629 |
|
753 |
|
1,276 |
|
1,456 |
|
|||||||||
Other operating expenses | 913 |
|
994 |
|
1,862 |
|
2,097 |
|
|||||||||
Rents and leases | 120 |
|
147 |
|
290 |
|
306 |
|
|||||||||
Depreciation and amortization | 318 |
|
350 |
|
618 |
|
685 |
|
|||||||||
Operating Profit (Loss) | (254) |
- |
281 |
|
(577) |
- |
61 |
|
|||||||||
Other Income (Expense): | |||||||||||||||||
Interest Expense - net | (7) |
- |
(4) |
|
(14) |
- |
(34) |
- |
|||||||||
Federal stimulus - Provider relief funds | 3,417 |
|
0 |
|
3,448 |
|
0 |
|
|||||||||
Loss on extinguishment of debt, net | 0 |
|
(160) |
- |
0 |
|
(160) |
- |
|||||||||
Gains on sale of assets | 5 |
|
86 |
|
13 |
|
193 |
|
|||||||||
Earnings from Continuing Operations before | |||||||||||||||||
Income Taxes | 3,161 |
|
203 |
|
2,870 |
|
60 |
|
|||||||||
Income Tax expense (benefit) | 15 |
|
0 |
|
15 |
|
0 |
|
|||||||||
Earnings from Continuing Operations | 3,146 |
|
203 |
|
2,855 |
|
60 |
|
|||||||||
Loss from Discontinued Operations, net of tax | (72) |
- |
(245) |
- |
(121) |
- |
(363) |
- |
|||||||||
Net Earnings (Loss) |
|
|
|
- |
|
|
|
- |
|||||||||
Earnings (Loss) Per Share from Continuing Operations: | |||||||||||||||||
Basic |
|
|
|
|
|||||||||||||
Diluted |
|
|
|
|
|||||||||||||
Loss Per Share from Discontinued Operations: | |||||||||||||||||
Basic |
|
|
|
|
|||||||||||||
Diluted |
|
|
|
|
|||||||||||||
Net Earnings (Loss) Per Share: | |||||||||||||||||
Basic |
|
|
|
|
|||||||||||||
Diluted |
|
|
|
|
|||||||||||||
Weighted Average Common Shares Outstanding: | |||||||||||||||||
Basic | 6,899 |
6,986 |
6,899 |
6,986 |
|||||||||||||
Diluted | 6,905 |
6,992 |
6,904 |
7,012 |
|||||||||||||
HEALTHCARE FACILITIES VOLUME STATISTICS | |||||||||||||||||
Hospital and Nursing Home Admissions | 77 |
97 |
141 |
219 |
|||||||||||||
Hospital and Nursing Home Patient Days | 4,670 |
6,890 |
9,914 |
13,851 |
|||||||||||||
SUMMARY BALANCE SHEETS | December 31, |
|
June 30, |
||||||||||||||
2020 |
|
2020 |
|||||||||||||||
ASSETS | |||||||||||||||||
Cash and Cash Equivalents |
|
|
|||||||||||||||
Accounts Receivable - net | 4,074 |
4,315 |
|||||||||||||||
Other Current Assets | 4,215 |
4,424 |
|||||||||||||||
Property Plant and Equipment, net | 5,688 |
5,324 |
|||||||||||||||
Long-term Assets | 3,304 |
2,724 |
|||||||||||||||
|
|
||||||||||||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||||||||||||
Accounts Payable |
|
|
|||||||||||||||
Unearned CARES Act Funds | 1,507 |
4,532 |
|||||||||||||||
Other Current Liabilities | 6,160 |
6,012 |
|||||||||||||||
Long-term Debt and Other Noncurrent Liabilities | 2,984 |
2,812 |
|||||||||||||||
Shareholders' Equity | 16,477 |
13,743 |
|||||||||||||||
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005791/en/
FAQ
What were SunLink Health Systems' earnings for Q2 2021 (SSY)?
How much did SunLink earn in the previous year for Q2 2020?
What is the net revenue decline for SunLink Health Systems in Q2 2021?
How much financial assistance did SunLink receive under the CARES Act?